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Abstract
Background: Amplification of the q21-q23 region on chromosome 1 is frequently found in
sarcomas and a variety of other solid tumours. Previous analyses of sarcomas have indicated the
presence of at least two separate amplicons within this region, one located in 1q21 and one located
near the apolipoprotein A-II (APOA2) gene in 1q23. In this study we have mapped and characterized
the amplicon in 1q23 in more detail.
Results: We have used fluorescence in situ hybridisation (FISH) and microarray-based comparative
genomic hybridisation (array CGH) to map and define the borders of the amplicon in 10 sarcomas.
A subregion of approximately 800 kb was identified as the core of the amplicon. The amplification
patterns of nine possible candidate target genes located to this subregion were determined by
Southern blot analysis. The genes activating transcription factor 6 (ATF6) and dual specificity
phosphatase 12 (DUSP12) showed the highest level of amplification, and they were also shown to
be over-expressed by quantitative real-time reverse transcription PCR (RT-PCR). In general, the
level of expression reflected the level of amplification in the different tumours. DUSP12 was
expressed significantly higher than ATF6 in a subset of the tumours. In addition, two genes known
to be transcriptionally activated by ATF6, glucose-regulated protein 78 kDa and -94 kDa (GRP78
and GRP94), were shown to be over-expressed in the tumours that showed over-expression of
ATF6.
Conclusion: ATF6 and DUSP12 seem to be the most likely candidate target genes for the 1q23
amplification in sarcomas. Both genes have possible roles in promoting cell growth, which makes
them interesting candidate targets.
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Background
Gains or amplification of the long arm of chromosome 1
is among the most common chromosomal abnormalities
in human neoplasia [1]. Local gains or high-level amplifi-
cation affecting 1q21-q23 is particularly frequent, and was
first described for sarcomas [2-4]. Sarcomas are a hetero-
geneous group of malignant tumours of various support-
ing- and connective tissues, ranging from the almost
benign well-differentiated liposarcomas (WDLS) to
aggressive tumour forms, such as fibrosarcomas, osteosa-
rcomas and malignant fibrous histiocytomas (MFH) [5].
Although infrequent, these tumours have been widely
studied at the molecular level, and this has provided
insight into mechanisms of importance for tumour devel-
opment in general. Notably, amplification and over-
expression of MDM2 and CDK4, representing alternative
pathways for inactivation of the tumour suppressors p53
and pRb, respectively, were first described for this group of
tumours [6,7].
A variety of solid tumours show amplification of 1q21-
q22, for instance 70–80 % of hepatocellular carcinomas
and 25–30 % of ovarian cancers [8,9]. Studies of renal
clear cell, hepatocellular and colorectal carcinomas
revealed a higher frequency of 1q21-q23 gains in meta-
static tumours [10,11], and gains of 1q21-q25 showed a
trend toward short overall survival in high-grade osteosa-
rcomas and neuroblastomas [12,13]. However, also sarco-
mas of borderline malignancy, such as WDLS, show
frequent amplification of 1q21-q23 [2,3,14], and 1q21 is
recurrently gained in desmoid tumours [15].
A more detailed molecular analysis of sarcomas has indi-
cated the presence of at least two separate amplicons
within 1q21-q23, located in 1q21 and 1q23, respectively
[16]. The amplicon in 1q21 was most frequent, and was
represented by a yeast artificial chromosome (YAC) clone,
789f2, located proximal to the S100-genes. The YAC
detected high amplification levels, and was subsequently
used to clone three novel candidate target genes that are
highly amplified and over-expressed in both sarcomas
and breast cancer [17]. The 1q23 amplicon was first
observed in one single tumour (LS21), where a probe for
the apolipoprotein A-II (APOA2) gene detected high
amplification levels [16]. Furthermore, the extent of the
amplified region around 1q21 as observed in comparative
genomic hybridisation (CGH) analyses was variable, cov-
ering only 1q21 in some tumours and 1q21-q23 or -q25
in other tumours [3,4]. These observations indicate that
also amplified genes located more distally of 1q21 may be
of importance in sarcoma development or progression.
We have now used a bacterial artificial chromosome
(BAC) contig of approximately 7 Mb, according to
Ensembl (http://www.ensembl.org, assembly December
14, 2004) [18] and the UCSC Genome Browser (http://
genome.ucsc.edu, assembly May 2004) [19], to map and
characterize the amplified region around APOA2 in LS21
using fluorescence in situ hybridisation (FISH). The two
BACs that showed particularly high copy numbers were
further analysed in nine additional sarcomas known to
have gains of the 1q21-q23 region [3,16] (and unpub-
lished results). Amplicon mapping was also done by
microarray-based CGH (array CGH). The amplification
patterns of nine possible candidate target genes were
determined by Southern blot analysis, and quantitative
real-time reverse transcription PCR (RT-PCR) was used to
determine the expression levels of the two candidate tar-
get genes that showed the highest level of amplification.
In addition, the expression level of two genes transcrip-
tionally activated by one of the candidate target gene was
analysed.
Results
Mapping of the 1q23 amplicon by FISH
Fifty-nine overlapping BACs, covering approximately 7
Mb in the q23 region of chromosome 1, were hybridised
to interphase nuclei from liposarcoma LS21. Figure 1A
shows the copy numbers detected by all the BACs.
Copy numbers varied throughout the region, but a subre-
gion defined by 12 overlapping BACs, RP11-312J18
through RP11-565P22, was highly amplified in this
tumour compared to the flanking areas. Furthermore, two
BACs within this amplified unit, RP11-110D4 and RP11-
195G14, detected higher copy numbers than any of the
other BACs tested. These two BACs are located approxi-
mately 400 kb distal to the APOA2 gene that originally
identified this amplicon. APOA2 is located in BAC RP11-
297K8 according to Ensembl. The localisation of BACs
RP11-110D4 and RP11-195G14 to 1q23 was confirmed
by hybridisation to metaphase nuclei from normal leuko-
cytes (not shown).
To further analyse the amplification frequency of the
sequences represented by these two BACs, we determined
the copy numbers in nine additional sarcomas known to
have gains of 1q21-q23 [3,16], and unpublished results].
The results are presented in Figure 1B. In all cases, ampli-
fication was detected in a substantial fraction of the
nuclei, especially for LS3x and MS8x. Only two tumours,
LMS2x and LS6, showed normal copy numbers in more
than 60 % of the nuclei.
The borders of the amplicon were in addition defined for
LS3x and MS8x, where high-level amplification was found
in 20–50 % of the nuclei. Four BACs located proximal and
three located distal to the two BACs detecting the highest
copy number were hybridised to interphase nuclei (Figure
1C). The amplicon in LS3x was represented by a few moreMolecular Cancer 2005, 4:39 http://www.molecular-cancer.com/content/4/1/39
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DNA copy number by FISH Figure 1
DNA copy number by FISH. (A) FISH analysis with 59 BACs on interphase nuclei from liposarcoma LS21. The BACs are 
listed from the centromeric to the telomeric side. The colour of the shading indicates the range of signals observed per 
nucleus, and the area the percentage of nuclei within each group of signals. The localisation of APOA2 in BAC RP11-297K8 is 
indicated, as well as the distance position of some of the BACs (the intervals are not equal since the BACs are not distributed 
evenly throughout the region). The two BACs used further in Figure 1B are highlighted, and the BACs used for array CGH in 
Figure 2 are marked with an asterisk (*). There is a gap of approximately 200 kb between BACs RP11-297K8 and RP11-5K23. 
After these analyses were performed, the gap was covered by the BAC RP11-122G18. Since no more material is available from 
LS21, this BAC has not been tested. (B) FISH analysis with BACs RP11-110D4 and RP11-195G14 on interphase nuclei from 10 
sarcomas (LMS, leiomyosarcoma; LS, liposarcoma; MFH, malignant fibrous histiocytoma; MS, malignant schwannoma, suffix 'x', 
xenograft). (C) FISH analysis with four BACs proximal and three distal of RP11-110D4 and RP11-195G14 on interphase nuclei 
from LS3x, LS21 and MS8x.
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BACs than the amplicon in LS21 and MS8x. For all three
tumours, BACs RP11-110D4 and RP11-195G14 detected
the highest level of amplification.
Mapping of the 1q23 amplicon by array CGH
Mapping of the 1q23 amplicon was also done by array
CGH. The 10 tumours analysed by FISH were hybridised
to a genomic microarray covering the minimal tiling-path
of the 1q12-q25 region. The results from 15 BACs, cover-
ing the region in 1q23 that showed highest amplification
level by FISH (Figure 1A), are presented here. The dataset
with these 15 BACs can be viewed in the microarray data-
base ArrayExpress (http://www.ebi.ac.uk/arrayexpress,
accession number E-MEXP-427) [20].
Figure 2 shows the relative copy numbers compared to a
normal reference of the overlapping BACs. In four of the
tumours, amplification levels above 3-fold were observed,
whereas the relative copy number of all the BACs was
lower in the other six tumours. For MS8x, the subregion
covered by BACs RP11-5K23 through RP11-384L19
showed the highest copy number, with RP11-195G14 and
RP11-456P18 detecting relative copy numbers of more
than 14. For LS6, the highest copy number was detected
by RP11-227F8. LS21 showed relative copy numbers of 5–
6 of the region covered by RP11-5K23 through RP11-
456P18, but a higher level of the region covered by BACs
RP11-312J18 through RP11-297K8, with RP11-137A12
and RP11-297K8 detecting a relative copy number of 7.
DNA copy number by array CGH Figure 2
DNA copy number by array CGH. Relative DNA copy number of the region represented by BACs RP11-404F10 through 
RP11-565P22 in 10 sarcomas. The localisation of BACs RP11-381D2, RP11-110D4, RP11-195G14 and RP11-336H14 is based 
on previous contig maps from the Wellcome Trust Sanger Institute (dotted line), since these are removed from the minimal til-
ing-path in Ensembl. *BAC RP11-122G18 is not present in the array.
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These two BACs detected the highest copy number also in
LS43.
The array CGH results showed in addition other clusters
of BACs detecting high copy numbers (data not shown),
indicating the presence of several separate amplicons
within the 1q12-q25 region, which will be described in a
later publication.
Identification of candidate target genes
Ensembl and the UCSC Genome Browser were used to
search for possible candidate target genes. Based on
sequence information, these programs visually display
possible open reading frames, as well as predicted and
known genes.
BACs RP11-110D4 and RP11-195G14, used here for FISH
and array CGH, have later been omitted from the minimal
tiling-path (Ensembl). The overlapping BACs RP11-5K23,
RP11-474I16 and RP11-456P18, which constitute the
minimal tiling-path, now represent the corresponding
region.
Within the approximately 800 kb region covered by the
BACs RP11-5K23 through RP11-384L19, 11 genes were
mapped according to Ensembl. The genes are FCGR2A, -
Gene copy number by Southern blot analysis Figure 3
Gene copy number by Southern blot analysis. Relative copy number of nine of the candidate target genes normalized 
with APOB in 10 sarcomas. The localisation of BACs RP11-110D4 and RP11-195G14 is based on previous contig maps from the 
Wellcome Trust Sanger Institute (dotted line), since these are removed from the minimal tiling-path in Ensembl. Gene localisa-
tions are based on Ensembl and the UCSC Genome Browser, with the genes listed from the centromeric to the telomeric side. 
Of the genes located in BACs RP11-297K8 and RP11-122G18, only APOA2 is shown. The densitometrically determined levels 
of amplification are divided into five categories as indicated.
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2B, and -3A, a family of low affinity immunoglobulin
gamma FC receptors; HSPA6, heat shock 70 kDa protein
6; DUSP12, dual specificity phosphatase 12; ATF6, activat-
ing transcription factor 6; OLFML2B, olfactomedin-like
2B; three genes referred to by RefSeqID: NP_116127, FC
receptor homolog expressed in B cells (FREB);
NP_055512, C-terminal PDZ domain ligand of neuronal
nitric oxide synthase (CAPON) and NP_001002901, with
no description; and one "novel" gene.
The UCSC Genome Browser indicated the same genes as
Ensembl, and in addition FCGR3B, another member of
the low affinity immunoglobulin gamma FC receptors
family.
Southern blot analysis of the candidate target genes
Copy numbers of nine of the candidate target genes were
further analysed by Southern blot analysis. The relative
copy numbers of the genes compared to APOB are pre-
sented in Figure 3. The candidate target genes that were
not tested were one "novel" gene, one gene with RefSeqID
(both with no description), and OLFML2B, which
appeared in Ensembl after the analyses were completed.
For tumours LS3x, LS21, LS43 and MS8x, the genes ATF6
and DUSP12 showed the highest amplification level in
general, 3–5 fold in LS3x and 5–10 fold in LS21 and LS43
(except ATF6), and particularly high copy numbers (>10
fold) in MS8x. FREB also showed high amplification lev-
els, except in MS8x where the level was 5-fold (approxi-
mately three times less than ATF6 and DUSP12). For the
Gene expression level by quantitative real-time RT-PCR Figure 4
Gene expression level by quantitative real-time RT-PCR. Relative expression level of the genes ATF6, DUSP12, GRP78 
and GRP94 in 10 sarcomas. The expression levels have been normalized with the average expression of the endogenous con-
trol genes B2M, GAPDH and TBP. The average relative expression level of the tumours with normal copy number of ATF6 and 
DUSP12 (LS2, LS6 and MFH36) has been set to 1. The relative copy number of ATF6 and DUSP12 determined by Southern blot 
analysis (Figure 3) is also shown.
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other six tumours, the amplification level of all the genes
was either normal or 2–3 fold.
APOA2 showed the same amplification levels as identified
previously [16], except that the copy number increase was
determined to be 5–10 fold instead of >10 fold in LS21,
and 2–3 fold instead of <2 fold in LMS15, either because
of experimental variation or because different parts of the
tumours were analysed. APOA2 is located in BAC RP11-
297K8 (Ensembl). By FISH analysis, RP11-297K8
detected high-level amplification in LS21 (32 % of the
nuclei), LS3x (13 % of the nuclei) and MS8x (16 % of the
nuclei) (Figure 1C), as one would expect.
Expression analysis of the candidate target genes by 
quantitative real-time RT-PCR
Quantitative real-time RT-PCR was used to determine the
expression levels of the two genes ATF6 and DUSP12,
which showed the highest level of amplification by South-
ern blot analysis. In addition, the expression level of two
genes known to be transcriptionally activated by ATF6 was
analysed, GRP78 and GRP94, glucose-regulated protein
78 kDa and -94 kDa. Figure 4 shows the expression level
of ATF6, DUSP12, GRP78 and GRP94 compared to the
average expression of the endogenous control genes β-2-
microglobulin (B2M), glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) and TATA box binding protein
(TBP). The average relative expression level of the
tumours with normal copy number of ATF6 and DUSP12
(LS2, LS6 and MFH36) has been set to 1.
LS21 and MS8x showed the highest level of expression of
both candidate target genes, ATF6 was over-expressed 8–9
fold whereas DUSP12 was over-expressed 11-fold in LS21
and 25-fold in MS8x. LS3x showed 3-fold over-expression
of both genes, and for LMS2x and MFH19, DUSP12 was
over-expressed 2–3 fold whereas ATF6 was expressed at
the same level as the three tumours with normal copy
number. LMS15 and LS43 showed the same expression
levels of both ATF6 and DUSP12 as the tumours with nor-
mal copy number of the genes.
DUSP12 was significantly higher expressed than ATF6 in
LMS2x, MFH19, MS8x (all p < 0,001), LS21 and LS43
(both p < 0,01), whereas ATF6 was significantly higher
expressed than DUSP12 in LMS15 (p < 0,01). There was
no significant difference in expression of the two genes in
the rest of the tumours.
GRP78  and  GRP94  were over-expressed in the same
tumours that showed over-expression of ATF6.  GRP78
was over-expressed 8-fold in MS8x, 5-fold in LS21 and 3-
fold in LS3x, whereas GRP94 was over-expressed 3-fold in
LS3x and 2-fold in LS21 and MS8x. In addition, MFH19
showed a 2-fold increase of both genes, whereas LMS2x
showed a 2-fold increase for only GRP78. LMS15 and
LS43 showed the same expression level of both GRP78
and GRP94 as the tumours with normal copy number of
ATF6 and DUSP12, as they did for ATF6 and DUSP12.
Discussion
CGH analyses of sarcomas show that the amplified part of
1q is variable. In some tumours, only 1q21 is highly
amplified, whereas other cases have amplification of the
whole 1q21-q23 or 1q21-q25 region [3,4]. These observa-
tions suggest the presence of multiple, separate amplicons
each containing target genes expected to be important for
the development or progression of these tumours.
In this study, we did FISH with a contig of BACs spanning
7 Mb around APOA2 to map and characterize this ampli-
con in more detail in liposarcoma LS21, which showed
the highest copy number of APOA2 in previous analyses
[16]. Our results showed that the core of the amplicon
could be defined by 12 partly overlapping BACs (Figure
1A). The two BAC clones that detected the highest ampli-
fication levels, RP11-110D4 and RP11-195G14, were
located approximately 400 kb distally of APOA2. Partial
mapping of the amplicon in two other tumours con-
firmed that the most amplified part was covered by these
two BACs (Figure 1C), which detected moderate to high-
level amplification in eight of the 10 sarcomas analysed
(Figure 1B).
The 1q21 amplicon, as represented by YAC 789f2, was
present in all tumours with 1q21-q23 amplification ana-
lysed here [3,16] (and unpublished results), and it was
generally present at higher copy numbers than the ampli-
con near APOA2 in 1q23. This pattern seemed neither to
be dependent on the sarcoma subtype, nor on the aggres-
siveness of the tumour. Both amplicons were for instance
observed in WDLS (LS2 and LS21) as well as in the more
aggressive leiomyosarcomas. However, the results pre-
sented here indicate that target genes located in 1q23 may
be important for tumour development or progression in a
subset of sarcomas, as this clearly is a separate amplicon.
Amplicon mapping was confirmed by array CGH using
tiling-path probes for this region (Figure 2). For the most
amplified subregion identified by FISH, four of the
tumours showed a variable amplification pattern, whereas
the other six tumours showed a relative copy number
between 1 and 3. The approximately 800 kb region cov-
ered by the BACs RP11-5K23 through RP11-384L19
appeared to be the core of the amplicon, where LS6, LS21
and especially MS8x showed high amplification levels.
But for LS21 and LS43, the region covered by the BACs
RP11-312J18 through RP11-5K23 also showed high lev-
els, suggesting that additional genes may be important for
these two cases.Molecular Cancer 2005, 4:39 http://www.molecular-cancer.com/content/4/1/39
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The results obtained by FISH and array CGH were in gen-
eral consistent, but differences were also observed, in par-
ticular for tumours LS3x and LS43. FISH detected high
copy numbers in a substantial fraction of the cells in LS3x,
whereas array CGH detected a relative copy number
around 3. For LS43 it was the other way around, with
higher copy numbers detected by array CGH than FISH.
Different pieces of the tumour were used to make inter-
phase nuclei for FISH and isolate DNA for array CGH, and
the observed discrepancy could thus be explained by
tumour heterogeneity. Heterogeneous amplification sta-
tus has been detected previously for some tumours, like
LS21 [16]. Also, normal cells in the tumours would cause
amplification levels of the cancer cells to be underesti-
mated by array CGH, and a subpopulation of cells with
high amplification levels may go undetected. FISH analy-
sis, although very laborious, would however detect such a
subpopulation.
In order to identify possible candidate target genes we
used Ensembl and the UCSC Genome Browser, and
Southern blot analysis was performed to determine the
copy numbers of nine of the candidate target genes (Fig-
ure 3). For tumours LS3x, LS21, LS43 and MS8x, the genes
ATF6 and DUSP12 showed the highest amplification level
in general, suggesting that one of them may be the target
for this amplification. Both genes were located within the
two BACs that detected the highest level of amplification.
Dual specificity phosphatase 12 (DUSP12) is a member of
the VH1-like dual specificity subfamily of protein phos-
phatases, which may dephosphorylate both phosphoser-
ine/threonine and phosphotyrosine residues [21]. This
gene is also termed YVH1, being the Homo sapiens
ortholog of the Saccharomyces cerevisiae gene YVH1 pro-
tein-tyrosine phosphatase. Little is known about the
human DUSP12/YVH1 protein function, but S. cerevisiae
YVH1 is involved in cell growth, meiosis and sporulation
[22], and inactivation of the S. cerevisiae YVH1 gene results
in a striking increase in yeast doubling time [23]. A similar
effect has been observed in the opportunistic fungal path-
ogen Candida albicans, where YVH1 also contributes to
pathogenicity [24]. Interestingly, the human YVH1 gene
has been shown to rescue the slow growth defect in yeast
caused by disruption of the S. cerevisiae YVH1 gene [25].
Since DUSP12 may be involved in cell proliferation, it is
possible that amplification of DUSP12 stimulates tumour
growth.
In addition, S. cerevisiae YVH1 has been shown to interact
with the yeast pescadillo homolog (YPH1) [26], and this
interaction has also been observed in the malaria parasite
Plasmodium falciparum with the orthologs of YVH1 and
pescadillo [27]. Pescadillo is essential for ribosome bio-
genesis, nucleogenesis and mammalian cell proliferation
[28,29], and disruption to its function results in cell cycle
arrest [29]. An increased expression of pescadillo protein
has been demonstrated in malignant cells [28], implying
that pescadillo may contribute toward tumour progres-
sion. Thus, the interaction between YVH1 and YPH1 also
connects  DUSP12/YVH1  to cell proliferation and cell
cycle regulation.
Activating transcription factor 6 (ATF6) is a member of the
basic-leucine zipper (bZIP) family of transcription factors.
It is involved in the endoplasmic reticulum (ER) stress
response pathway, and activates expression of genes
induced by the ER stress response [30] (and references
therein). Interestingly, the ER stress response is already
implicated in sarcoma biology, as the CHOP/GADD153
gene, involved in these processes [31], is translocated in
myxoid liposarcomas [32] and also sometimes amplified
in sarcomas [33].
ATF6 has been shown to activate the promoters of the
genes glucose-regulated protein 78 kDa and -94 kDa
(GRP78 and GRP94) [34,35], which function as ER chap-
erones.  GRP78  is also termed immunoglobulin heavy
chain binding protein (BiP) and heat shock 70kDa pro-
tein 5 (HSPA5), while GRP94 is also termed tumour rejec-
tion (gp96) antigen 1 (TRA1).
GRP78  and  GRP94  have been shown to protect cells
against apoptosis [36,37] (and references therein), and
this anti-apoptotic function suggests that induction of
these genes could lead to cancer progression and drug
resistance in neoplastic cells. Several studies have corre-
lated over-expression of GRP78 and GRP94 with tumour
growth [36,37] (and references therein), most likely
because of inhibition of apoptosis. Thus, it is possible that
amplification of ATF6 could lead to over-expression of
GRP78  and  GRP94, thereby giving the cells a growth
advantage or resistance to chemotherapy.
The expression levels of ATF6 and DUSP12 were deter-
mined by quantitative real-time RT-PCR (Figure 4), and in
general the expression level of ATF6 and DUSP12 reflected
the amplification level in the different tumours. LS21 and
MS8x showed the highest level of expression, with
DUSP12 being as high as 25-fold over-expressed in MS8x.
DUSP12 was expressed significantly higher than ATF6 in
these two tumours (p < 0,001 for MS8x and p < 0,01 for
LS21), and also in LMS2x and MFH19 (both p < 0,001).
Thus, except for LS3x, DUSP12  is significantly higher
expressed than ATF6 in all the tumours that showed at
least 2-fold over-expression of either or both genes, sug-
gesting that DUSP12 may be the real target for the ampli-
fication.Molecular Cancer 2005, 4:39 http://www.molecular-cancer.com/content/4/1/39
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In order to investigate whether amplified ATF6 is active,
the expression levels of GRP78 and GRP94 were deter-
mined (Figure 4). Interestingly, both genes were also over-
expressed in the tumours that showed high expression of
ATF6 (LS3x, LS21 and MS8x). GRP78 showed especially
high levels, being over-expressed 8–9 fold in LS21 and
MS8x. In addition, expression of both genes was increased
2-fold in MFH19 and also in LMS2x for GRP78, two
tumours with similar expression level of ATF6  as the
tumours with normal copy number of ATF6. However, the
expression level of GRP78  and  GRP94  in these two
tumours is lower than what is observed in the tumours
with over-expression of ATF6, and may possibly be caused
by other regulatory mechanisms. Thus, amplification and
over-expression of ATF6 seem to cause over-expression of
particular GRP78 but also GRP94, thereby implying that
amplification of ATF6 has a functional role.
Conclusion
Based on their consistent association with this amplicon
and possible roles in promoting cell growth, both ATF6
and DUSP12 represent interesting candidate target genes
for the 1q23 amplification in sarcomas. DUSP12 seems to
be the most likely target based on the significantly higher
expression in a subset of the tumours, but since relevant
genes activated by ATF6  also are highly expressed in
tumours with over-expression of ATF6, both genes are
considered potential targets. Further functional analyses
are required to determine the role of these proteins in sar-
coma development or progression.
Methods
Specimens
Ten sarcomas with known alterations of 1q21-q23 were
analysed in this study, five liposarcomas (LS), two leiomy-
osarcomas (LMS), two malignant fibrous histiocytomas
(MFH) and one malignant peripheral nerve sheath
tumour (MPNST) (previously termed malignant schwan-
noma, MS). Histopathological and clinical characteristics
of these tumours have been previously described [16,17].
Fluorescence in situ hybridisation (FISH)
Fifty-nine overlapping BACs were used as probes for FISH.
All the BACs were from the clone library RPCI-11 [38],
kindly provided by the Wellcome Trust Sanger Institute
http://www.sanger.ac.uk. The precise localisation of each
BAC was based on sequence alignment by basic local
alignment search tool (BLAST), performed by the Well-
come Trust Sanger Institute.
BAC DNA was isolated by standard methods and labeled
with biotin-16-dUTP or digoxygenin-11-dUTP (Roche) by
use of the BioNick Labeling System (Invitrogen). For each
hybridisation, 300 ng of labeled DNA was ethanol precip-
itated together with 10 µg human Cot-1 DNA (Invitro-
gen). The precipitated DNA was dissolved in 15 µl
hybridisation buffer (50 % formamide, 10 % dextran sul-
phate, 2 × SSC).
Preparation of interphase nuclei from tumour tissue was
done as previously described [16]. The slides were thawed
and immersed in 70 % ethanol for at least 1 hour, air-
dried and treated with 0,4 mg/ml pepsin for 20 minutes at
37°C. After this, the slides were washed three times for 5
minutes in 1 × PBS, fixated in 1 % formaldehyde/1 × PBS
for 10 minutes at room temperature and washed three
times for 5 minutes in 1 × PBS. The slides were dehydrated
in ethanol (70, 90, 96 and 100 %) and air-dried.
The slides were denatured for 2 minutes at 74°C in 70 %
de-ionized formamide/2 × SSC, immediately transferred
to ice-cold 70 % ethanol, further dehydrated and air-
dried. The labeled DNA was denatured for 10 minutes at
80°C, prehybridised for at least 30 minutes at 37°C and
applied to slides at room temperature. Hybridisation was
performed overnight at 37°C. After hybridisation, slides
were washed three times for 10 minutes in 50 % forma-
mide/2 × SSC at 45°C, and three times for 10 minutes in
0,1 × SSC at 45°C.
Signals from biotin-labelled probes were detected with
avidin-Cy3 (Amersham Biosciences), and for detection of
digoxygenin-labelled probes we used a FITC-labelled
sheep-anti-digoxygenin antibody followed by ALEXA
488-labelled donkey-anti-sheep (Molecular Probes). For
probes that gave weak signals, signals were amplified by
deposition of FITC- or biotin-labelled thyramides, essen-
tially as described in the protocols supplied by the manu-
facturer (TSA-direct and -indirect, NEN™ Life Science
Products). Signals from biotinylated thyramides were
detected with FITC-labelled streptavidin (NEN). The
interphase nuclei were counterstained with 4',6-diamino-
2-phenylindole (DAPI) and mounted in anti-fade solu-
tion (Vector Laboratories).
Hybridised slides were examined visually using a Zeiss
Axioplan microscope equipped with appropriate filters
for excitation of DAPI, DAPI/FITC or DAPI/Rhodamine
(Cy3). The slides were manually scanned at 63 × or 100 ×
magnification with DAPI excitation to localise the inter-
phases. For each probe, the number of spots was counted
in at least 100 nuclei. Amplification levels were grouped
into three categories; normal (two signals), moderate (3–
9 signals) and high (10 or more signals).
Microarray-based comparative genomic hybridisation 
(array CGH)
Genomic microarrays covering the 1q12-q25 region were
made using overlapping BACs and P1 artificial chromo-
somes (PACs). The BACs were from the clone libraryMolecular Cancer 2005, 4:39 http://www.molecular-cancer.com/content/4/1/39
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RPCI-11 [38], whereas the PACs were from the clone
libraries RPCI-1, -3, -4 and -5. All clones were kindly pro-
vided by the Wellcome Trust Sanger Institute http://
www.sanger.ac.uk. The precise localisation of each BAC
and PAC was based on sequence alignment by BLAST, per-
formed by the Wellcome Trust Sanger Institute.
The results from 15 of the BACs, covering the region in
1q23 that showed highest amplification level by FISH, are
presented here. The dataset with these 15 BACs has been
submitted to ArrayExpress, the microarray database of the
European Bioinformatics Institute (http://www.ebi.ac.uk/
arrayexpress, accession number E-MEXP-427) [20].
Isolation of BAC and PAC DNA, amplification by DOP-
PCR and preparation of microarrays were done as previ-
ously described [39]. The PCR products were arrayed in
quadruplicate onto amine-binding slides (CodeLink,
Amersham Biosciences) using a MicroGrid II arrayer
(BioRobotics).
Genomic DNA from tumour tissues was isolated by stand-
ard methods as described previously [40]. Normal female
or male DNA (Promega) was used as a reference. Labeling
of the DNA was done as previously described [39], with a
few modifications. Here, 500 ng total genomic DNA was
labeled using 1,5 µl 1 mM Cy3-dCTP or Cy5-dCTP (Amer-
sham Biosciences) in a total volume of 100 µl.
The labeled tumour and reference DNA were combined
and ethanol precipitated together with 135 µg human
Cot-1 DNA (Invitrogen). The precipitated DNA was dis-
solved in 108 µl hybridisation buffer (50 % formamide,
10 % dextran sulphate, 4 % SDS, 2 × SSC) and 4 µl 100
mg/ml yeast tRNA (Invitrogen). The DNA was denatured
for 10 minutes at 70°C and prehybridised for at least 30
minutes at 37°C.
Hybridisation was performed using an automated hybrid-
isation station, GeneTAC (Genomic Solutions/Perkin
Elmer), agitating the hybridisation solution for 48 hours
at 37°C. After hybridisation, the slides were washed with
50 % formamide/2 × SSC at 48°C, 2 × SSC/0,1 % SDS at
48°C and PN-buffer (0,1 M NaH2PO4  plus 0,1 M
Na2HPO4 to obtain pH 8/0,1 % NP-40) at 25°C. For all
three solutions, the hybridisation station washed 5 cycles
with a flow time of 20 seconds and a hold time of 40 sec-
onds for each cycle. After removal from the hybridisation
station, the slides were rinsed briefly in 0,05 × SSC and
dried by spinning in a centrifuge.
The arrays were scanned by use of an Agilent G2565BA
scanner (Agilent Technologies). The acquired microarray
images were analysed using GenePix Pro 4.1 (Axon Labo-
ratories). The spots were automatically segmented and
manually adjusted where necessary. The fluorescent inten-
sities and the local background of the two dyes were cal-
culated for each spot. Further data processing, including
filtering and normalisation, was done using M-CGH, a
MATLAB toolbox specifically designed for this purpose
[41].
Southern blot analysis
Eleven human cDNA clones were used as probes for
Southern blot analysis. The clones for the nine candidate
target genes were from the I.M.A.G.E. Consortium [LLNL]
cDNA clones library http://image.llnl.gov[42], provided
by Research Genetics. The I.M.A.G.E. Consortium
CloneID and GenBank accession numbers of the clones
are as follows: ATF6 (417251, W87752); CAPON
(1860405, AI198232); DUSP12 (843328, AA485951);
FCGR2A (868380, AA634109); FCGR2B (138369,
R68106); FCGR3A (450155, AA703460); FCGR3B
(51447, H20822); FREB (291871, W02963) and HSPA6
(2310335, AI654494).
In addition, a cDNA for APOA2 [43] was used. As a con-
trol probe, the apolipoprotein B (APOB) gene, located in
the p24 region of chromosome 2, was used [44]. Previous
work has shown no amplification of this chromosomal
region in neither our sarcoma panel [3,4,45] nor liposar-
comas from other groups [2,46]. All cDNA clones were
sequence verified.
DNA extraction from tumour tissues, digestion, prepara-
tion of filter blots and hybridisation were done as previ-
ously described [40]. Quantitation of signal intensity was
done by two-dimensional densitometry on a Molecular
Dynamics laser densitometer. To correct for unequal sam-
ple loading, the gene-specific signals were calibrated to
the relative signals obtained from the APOB  control
probe. Amplification levels were calculated by compari-
son with signals from normal controls (leukocytes), and
grouped into five categories; <2 (normal), 2–3, 3–5, 5–10
and >10.
Quantitative real-time reverse transcription PCR (RT-
PCR)
Quantitative real-time RT-PCR was performed using Taq-
Man® Gene Expression Assays (Applied Biosystems). The
expression level was determined for the candidate target
genes ATF6 (assay ID Hs00232586_m1) and DUSP12
(assay ID Hs00170898_m1). In addition, the expression
level of GRP78 (also termed HSPA5, assay ID
Hs00946088_g1) and GRP94 (also termed TRA1, assay
ID Hs00427665_g1) was analysed. The genes B2M (assay
ID Hs99999907_m1), GAPDH (assay ID
Hs99999905_m1) and TBP (assay ID Hs99999910_m1)
were used as endogenous controls for normalization.
These housekeeping genes were chosen since they showedMolecular Cancer 2005, 4:39 http://www.molecular-cancer.com/content/4/1/39
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low variability by microarray expression profiling of our
panel of sarcomas (Namløs, Berner, Myklebost et al.,
unpublished).
Frozen tumour tissue was pulverized in liquid nitrogen,
and total RNA was extracted using Trizol (Invitrogen)
according to the manufacturer's instructions. Universal
Human Reference RNA (Stratagene) was used as a refer-
ence. cDNA synthesis was performed using the High-
Capacity cDNA Archive Kit, essentially as described in the
protocols supplied by the manufacturer (Applied Biosys-
tems).
The PCR amplification was performed according to the
manufacturer's instructions using the ABI Prism 7000
Sequence Detection System (Applied Biosystems). The
cycling conditions comprised 10 minutes polymerase
activation at 95°C and 40 cycles of 95°C for 15 seconds
and 60°C for 1 minute. Each assay included (in tripli-
cate): a standard curve of four serial dilutions of the Uni-
versal Human Reference RNA cDNA (ranging from 50 ng
to 50 pg), a no-template control and 2 ng of each tumour
cDNA.
Gene expression in the tumours was determined from the
standard curves, and the expression level of ATF6,
DUSP12,  GRP78  and  GRP94  was normalized with the
average expression of the three endogenous controls.
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